213
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Neutrophil to Lymphocyte Ratio (NLR) is a Better Tool Rather than Monocyte to High-Density Lipoprotein Ratio (MHR) and Platelet to Lymphocyte Ratio (PLR) in Central Retinal Artery Occlusions

, MD & , MDORCID Icon
Pages 997-1001 | Received 28 Oct 2019, Accepted 03 Jan 2020, Published online: 20 Feb 2020
 

ABSTRACT

Purpose: To evaluate the predictive value of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to high-density lipoprotein (HDL) ratio (MHR) and blood lipid profile in central retinal artery occlusion (CRAO) patients.

Methods: We included 37 patients with a diagnosis of CRAO and 36 healthy subjects with similar age-sex in the study. We analyzed the medical records of peripheral blood samples retrospectively. NLR, PLR, MHR were obtained by simple manually calculations.

Results: CRAO patients had significantly higher mean NLR in comparison with healthy subjects (p: 0.009). The groups were similar in regard to mean PLR (p: 0.864) and mean MHR (p: 0.581). A cutoff value of >1.62 for NLR was found to be a diagnostic tool in CRAO. The sensitivity and specificity for this cutoff point was 83.8% and 55.6%, respectively.

Conclusion: NLR rather than MHR and PLR may be a beneficial marker for the development of CRAO.

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.